Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

NCT04287855 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma in Relapse
Multiple Myeloma, Refractory

Interventions

DRUG: Isatuximab
DRUG: Carfilzomib
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Poitiers University Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]